Nucleai released Amikta, a full-cell segmentation model for multiplexed imaging (mIF) that resolves nucleus, cytoplasm, and membrane across diverse cell types and marker identities.
Published
Signal category
Research & Knowledge
Quote
“Amikta, our full-cell segmentation model for mIF”
— Nucleai team
Company
Nucleai
Turning tissue into actionable intelligence: the evidence behind why therapies work, and who they work for.
- Industry
- Software Development
- Location
- Chicago, US
- Company size
- 68 employees
Nucleai is the tissue intelligence layer for drug development and translational research. We pair AI-driven multimodal image analysis across H&E, IHC, mIF, and spatial transcriptomics with clinical outcomes linkage, delivered through our AI-driven computational platform and expert-led analysis. The result: structured tissue intelligence built to answer the two questions that determine a therapy's path: why does it work, and which patients will benefit. We work with two groups: biopharma sponsors across oncology, immunology, and metabolic disease turning tissue into program decisions, and the spatial biology platforms and research centers generating spatial biology data.
Founded 2018